ALEPH-FARMS
3.11.2021 11:05:08 CET | Business Wire | Press release
Aleph Farms , the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced its detailed roadmap for achieving net zero carbon. In April 2020 , Aleph Farms first announced it would reach net zero within its operations by 2025, and throughout its entire supply chain by 2030. Today, Aleph Farms’ net zero carbon roadmap details its scope for achievement, strategic partnerships and the investments necessary to advance its environmental goals and business bottom line as the company delivers its quality cultivated beef steaks.
“The production of food is one of the largest sources of greenhouse gas emissions on the planet today, and a driving reason why Aleph Farms is making long-term sustainability a top priority,” said Dr. Lee Recht, VP sustainability at Aleph Farms. “Our roadmap represents significant research that will enable us to fulfill our commitment to total net zero within this decade and we strongly encourage other companies within the agrifood ecosystem to work to eliminate their carbon footprint as soon as possible.”
Aleph Farms’ roadmap to net zero carbon was created in partnership with Aimee Christensen, CEO of Christensen Global Strategies and a world-renowned expert in climate change and sustainability strategies. The roadmap to reduce the company’s carbon footprint includes optimized energy efficiency, transitioning renewable energy, offsetting and/or insetting unavoidable remaining emissions via reinvestment in decarbonizing Aleph Farms’ own production lines and supply chains.
“By building a company with a net zero mindset from nearly day one, Aleph Farms is pioneering the smart clean growth that all companies must take,” Christensen said. “By investing in energy efficiency and direct renewable energy supplies and similar strategies within its supply chain, Aleph Farms will benefit their bottom line now and even more in the future as carbon is priced around the world.”
As part of its roadmap, Aleph Farms has also signed a Memorandum of Understanding (MoU) with ENGIE Impact , the sustainability consulting arm of ENGIE . The two companies will work together to ensure Aleph Farms’ operations are net-zero compatible from the get-go, integrating energy efficiency, circularity in energy, as well as renewable energy and other strategic investments across Aleph’s production line and supply chains.
“We are delighted to work with Aleph Farms to support their net-zero strategy and vision to transform the meat industry,” said Nicolas Lefevre-Marton, Managing Director, EMEAI at ENGIE Impact. “We are deeply committed to helping bold organizations of all sizes around the world develop the right decarbonization goals, roadmaps and execution strategies to successfully achieve net-zero.”
In addition, Aleph Farms’ commitment to net zero carbon is being supported by a partnership with CE Delft , to analyze the life cycle impacts of Aleph Farms’ production line and supply chain, identifying hotspots and working to optimize the overall ecological footprint including carbon, water, waste and more. CE Delft recently conducted a study that found cultivated meat has the potential to reduce the carbon footprint of beef production by 92% when utilizing renewable sources of energy.
Aleph Farms is co-hosting an event alongside Food Tank at this year’s COP26 in Glasgow, Scotland on November 9, 2021. The panel, A New Approach to Meat , will discuss what it takes to change the production of animal protein and improve environmental impact while maintaining farmers' livelihoods and food security. The company’s white paper, An Inclusive Transition to a Sustainable and Resilient Meat Sector , highlights how transformational net zero carbon production systems can complement sustainable agricultural practices, supplying nutritional food to the growing population and strengthening global food security. To learn more about Aleph Farms' path to sustainability, please visit aleph-farms.com/sustainability .
About Aleph Farms
Aleph Farms grows beef steaks, from non-genetically engineered, non immortalized cells isolated from a living cow, without slaughtering the animal and with a significantly reduced impact to the environment. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub of the Strauss Group, and Professor Shulamit Levenberg from the Biomedical Engineering Faculty at the Technion - Israel Institute of Technology. The company’s vision is to provide unconditional nutrition for anyone, anytime, anywhere. For more information, follow Aleph Farms on Instagram , Twitter , Facebook or LinkedIn or visit www.aleph-farms.com . Access the Aleph Farms press kit here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005338/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
